Associate Professor, Pathology and Laboratory Medicine, Boston University School of Medicine

Pathology

Dr. Karen Quillen, MD

Doctor Karen Quillen, MD works in the field of Pathology. She received awards:"Super Doctor". Dr. Karen Quillen is also a published doctor. She has 44 paper published. The most recent paper is: Methods of isolation and cryopreservation of stem cells from cord blood. Karen Quillen, MD accepts Medicare payments and is listed with Medicare.gov.

Publications

Hospital admissions following outpatient administration of high-dose melphalan and autologous SCT for AL amyloidosis.
Plerixafor-augmented peripheral blood stem cell mobilization in AL amyloidosis with cardiac involvement: a case series.
Safety and efficacy of high-dose melphalan and auto-SCT in patients with AL amyloidosis and cardiac involvement.
Successful long-term management of aneurysm-associated chronic disseminated intravascular coagulation with low molecular weight heparin.
Amyloid Deposits in the Bone Marrow of Patients with Amyloid Light Chain Amyloidosis Do Not Impact Stem Cell Mobilization or Engraftment.
A novel sickle hemoglobin: hemoglobin S-south end.
Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation.
High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study.
High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloi...
An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy.
Hypotensive transfusion reactions in patients taking angiotensin-converting-enzyme inhibitors.
Methods of isolation and cryopreservation of stem cells from cord blood.
Vascular erosion caused by a double-lumen central venous catheter during therapeutic plasma exchange.
Bortezomib and high-dose melphalan conditioning for stem cell transplantation for AL amyloidosis: a pilot study.
High-dose melphalan and autologous stem cell transplantation for AL amyloidosis: recent trends in treatment-related mortality and 1-year survival at a single institution.
Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis.
Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome.
Prevalence of RhD variants, confirmed by molecular genotyping, in a multiethnic prenatal population.
A practical strategy to reduce the risk of passive hemolysis by screening plateletpheresis donors for high-titer ABO antibodies.
Spontaneous rupture of the liver in a patient with systemic AL amyloidosis undergoing treatment with high-dose melphalan and autologous stem cell transplantation: a ca...
Long-term outcome of patients with monoclonal Ig deposition disease treated with high-dose melphalan and stem cell transplantation.
Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple Myeloma-associated AL amyloidosis.
Granulocyte transfusions in severe aplastic Anemia: an eleven-year experience.
Using neutrophil and lymphocyte VCS indices in ambulatory pediatric patients presenting with fever.
Utility of hematologic and volume, conductivity, and scatter parameters from umbilical cord blood in predicting chorioamnionitis.
Hepatic response after high-dose melphalan and stem cell transplantation in patients with AL amyloidosis associated liver disease.
Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions.
Febrile reactions occurring with second cycle of high-dose melphalan and SCT in patients with AL amyloidosis: a ''melphalan recall'' reaction.
Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone.
Reducing the risk of mistransfusion.
The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-st...
Prevalence of ceftriaxone-induced red blood cell antibodies in pediatric patients with sickle cell disease and human immunodeficiency virus infection.
Effect of hydroxyurea on immature reticulocyte fraction in sickle cell Anemia.
Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation.
Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
Low-dose recombinant activated factor VII in massively transfused trauma patients with coagulopathy.
Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65.
Quality improvement to decrease specimen mislabeling in transfusion medicine.
Clinical and molecular characteristics of patients with non-amyloid light chain deposition Disorders, and outcome following treatment with high-dose melphalan and auto...
Predictive factors for hematopoietic engraftment after autologous peripheral blood stem cell transplantation for AL amyloidosis.
Pericardial effusion: a rare presentation of adult T-cell Leukemia/lymphoma.

Schools

Queens University Faculty of Medicine
Brigham and Women39s Hospital

Procedures Preformed

HPC Transplantation (Stem Cell Transplant)
Plasmapheresis

Conditions Treated

Acute Leukemia
Anemia
Deep Vein Thrombosis (DVT)
Lymphoma
View All

Doctors Specialties

Hematology
Pathology

Accepted Insurances

Awards

Super Doctor

Education

Tufts Medical Center
Brigham and Women's Hospital
Queen's University at Kingston

Hospital

Boston Medical Center

Helpful Reviews

Give Anonymous Review

Medicare Facts

National Provider Identifier [NPI]	1750354130
Last Name Of The Provider	QUILLEN
First Name Of The Provider	KAREN
View All

Similar Doctors

	Dr. Drucilla J. Roberts, MD This Doctor is OpenDoctor Recommended.
	Dr. Theonia K. Boyd, MD This Doctor is OpenDoctor Recommended.
	Dr. William C. Schoene, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Judson M. Englert, MD
	Dr. Mana M. Parast, MD This Doctor is OpenDoctor Recommended.
	Dr. VanEsa Bijol, MD This Doctor is OpenDoctor Recommended.
	Dr. Parul Bhargava, MD This Doctor is OpenDoctor Recommended.